TRENDING: See Nvidia's Growing Appetite For Startup Investments Hims stock popped Wednesday after the telemedicine giant announced its long-awaited foray into offering testosterone replacement therapy. The announcement was highly anticipated given Hims & Hers Health (HIMS) has long discussed its plan to launch a testosterone replacement therapy, or TRT. There will be four options, offered in partnership with privately held Marius Pharmaceuticals. Pricing has yet to be outlined, but will likely run in the ra ...

Group 1 - Binary Tree Analytics (BTA) aims to provide transparency and analytics in capital markets instruments and trades, focusing on Closed-End Funds (CEFs), Exchange-Traded Funds (ETFs), and Special Situations [1] - BTA has over 20 years of investment experience and emphasizes delivering high annualized returns with a low volatility profile [1]

If you missed Apple's so-called a-dropping event, don't worry, we've got you covered. Here's everything you need to know in about a minute. First up, the iPhone Air.It's the first major redesign in years. Thinner, sleeker, and what Tim Cook calls the biggest leap ever for iPhone. Price tag $999.Next, the iPhone 17 lineup. That's the base model, Pro and Pro Max. Running from $799 to $1,199.All of them are more damage resistant and the Pros pack bigger batteries for longer life. AirPods Pro also got a long- a ...

Group 1 - The T. Rowe Price Dividend Growth ETF (TDVG) has surpassed $1 billion in assets under management (AUM), reaching approximately $1.06 billion, up from just under $900 million last month, indicating significant investor interest [1][2] - TDVG has experienced $155 million in net inflows over the last month, marking its fifth anniversary as an ETF, which is often seen as a milestone for assessing a fund's reliability [1][2] - The ETF focuses on mid and large-cap firms with sustainable dividend and earnings growth, emphasizing factors such as current dividend yield, balance sheets, and cash flow, which has led to a year-to-date return of 9.7%, outperforming the Factset Segment average of 8.8% [3] Group 2 - The active dividend strategy of TDVG is appealing amid rising market uncertainty, as it aims to identify strong dividend payers that are well-positioned for potential economic challenges [2][3] - The fund's consistent active approach to dividend payers since its inception has contributed to its growing popularity among investors, particularly in a volatile market environment [2][3] - Looking ahead, dividend-paying companies may present an attractive investment opportunity, especially in light of potential market volatility and declining economic indicators [3]

In today's article, we will analyse the PIMCO Active Bond Exchange-Traded Fund ETF (NYSE: BOND ) investment vehicle, which belongs to the financial category of exchange-traded funds (ETFs) and is managed and supervised by Pacific Investment ManagementAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not recei ...

Group 1 - The article analyzes the PIMCO Active Bond Exchange-Traded Fund ETF (NYSE: BOND), which is categorized under financial ETFs and managed by Pacific Investment Management [1] - The focus is on the investment vehicle's performance and management structure, highlighting its relevance in the current market [1] Group 2 - The article does not provide specific performance metrics or historical data regarding the ETF [2] - There are no recommendations or advice given regarding the suitability of the investment for particular investors [2]

President, CEO & Director Absolutely. Well, thank you for having us. We appreciate it. I'm Vipin Garg, President and CEO of Altimmune; and my colleague, Dr. Scott Harris, our Chief Medical Officer. Happy, excited to tell you about Altimmune. So we are developing a GLP-1 glucagon dual receptor agonist for the treatment of serious liver diseases such as MASH. We'll talk more about that. But really, the idea is this -- the drug is called pemvidutide is rationally designed to have both direct effects in the liv ...

t t t Bank of America downgraded psychiatric facility operator Acadia Healthcare (NASDAQ:ACHC) to Neutral from Buy on Wednesday, citing stronger-than-anticipated headwinds resulting from cuts to Medicaid state-directed payment programs. President Donald Trump's budget reconciliation package, dubbed the One Big Beautiful Bill, enacted in July, led T P th P u p H ...

Toro stock TTC is currently in Phase 18, the final stage of its 18-phase Adhishthana Cycle on the weekly charts. The stock has been trapped in a consolidation range for over 700 days, and based on the Adhishthana principles, this trend may persist through August 2026. Toro Stock: Poor Guna Triads at the Root of Underperformance Within the Adhishthana framework, Phases 14, 15, and 16 form the Guna Triads. These phases determine whether a stock can reach Nirvana in Phase 18, the culmination of the cycle. For ...

Question-and-Answer SessionWith that, we begin the Altimmune fireside chat, and we are excited to have you here. So for those who do not know the story of Altimmune, can you give us a brief background of yourselves and a brief background of the company at a higher level and what you're currently focused on?Vipin GargPresident, CEO & Director Absolutely. Well, thank you for having us. We appreciate it. I'm Vipin Garg, President and CEO of Altimmune; and my colleague, Dr. Scott Harris, our Chief Medical Offic ...